Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 04, 2015 8:07 PM ET


Company Overview of Zenyaku Kogyo Co., Ltd.

Company Overview

Zenyaku Kogyo Co., Ltd. develops dermatological and anti-cancer drugs. Its product includes Rituxan™, an anti-CD20 antibody for the treatment of B-cell Non-Hodgkin's Lymphoma. The company also develops OTC drugs. Zenyaku Kogyo Co., Ltd. was founded in 1950 and is based in Tokyo, Japan.

5-6-15 Otsuka


Tokyo,  112-8650


Founded in 1950


81 3 3946 1111


81 3 3946 1130

Key Executives for Zenyaku Kogyo Co., Ltd.

Chief Executive Officer and President
Compensation as of Fiscal Year 2015.

Zenyaku Kogyo Co., Ltd. Key Developments

Anthera Announces Termination of Blisibimod Partnership in Japan by Zenyaku

Anthera Pharmaceuticals, Inc. announced receipt of a termination notice from its development partner in Japan, Zenyaku, terminating the December 2014 Collaboration and License Agreement (the License Agreement") effective January 7, 2016. The termination was at will" and alleged no breach of the License Agreement by Anthera. At the time of the notification, no patients had been enrolled in any blisibimod clinical studies in the Zenyaku territory and Zenyaku had not purchased any blisibimod product from Anthera.

Anthera Pharmaceuticals, Inc. Enters into License Agreement with Zenyaku Kogyo Co., Ltd

On December 11, 2014, Anthera Pharmaceuticals Inc. entered into a license agreement with Zenyaku Kogyo Co., Ltd. pursuant to which the company granted Zenyaku an exclusive license to certain patent rights, know-how and other intellectual property relating to blisibimod. Under the agreement, Zenyaku obtained exclusive rights to develop, use, sell, have sold, offer for sale and import blisibimod and any related products containing any of blisibimod's binding domains, including but not limited to any pegylated blisibimod binding domain, certain rights to grant sublicenses and an option to expand the territory of the license to include China, Singapore, Taiwan, Philippines, Thailand, Malaysia, Vietnam, Indonesia and South Korea. The licensed patent rights include all patents controlled by Anthera or its affiliates relating to blisibimod, including those licensed to Anthera under that certain License Agreement dated December 18, 2007 between Anthera and Amgen Inc. as amended October 16, 2009 and November 26, 2014. Anthera retained the right to practice and grant licenses relating to blisibimod technology in all areas outside of the licensed territory, to manufacture and have manufactured compounds and products relating to blisibmod anywhere in the world and to conduct or have conducted clinical trials and other studies of compounds and products relating to blisibmod anywhere in the world. The development activities of both Anthera and Zenyaku will be overseen by a joint development committee. Under the terms of the License Agreement, Zenyaku assumes sole responsibility for the sale, marketing, promotion and commercialization of products relating to blisibimod in the licensed territory, and is obligated to use commercially reasonable efforts to market, promote, sell and commercialize licensed products in such territory.

Similar Private Companies By Industry

Company Name Region
Goryo Chemical, Inc. Asia
BioMedcore Inc. Asia
Orion Molecular Services Asia
Novozymes Japan Ltd. Asia
ImmunoFrontier, Inc. Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zenyaku Kogyo Co., Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at